A Phase 1/2a, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Trial of Oral ATRN-119 in Patients with Advanced Solid Tumors
A Phase 1/2a, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Trial of Oral ATRN-119 in Patients with Advanced Solid Tumors
Mechanism of Action
ATRN-119 selectively targets and binds to ATR, and inhibits its activity and ATR-mediated signaling. This blocks the downstream phosphorylation of the serine/threonine protein kinase checkpoint kinase 1 (CHK1). This results in the inhibition of DNA damage checkpoint activation, the disruption of DNA damage repair, and the induction of tumor cell apoptosis.
Purpose
In this study, the sponsor and investigators want to learn: How much of the study agent can be given with an acceptable level of side effects
- The effects of the study agent (good and bad)
- How much of the study agent is absorbed into the blood and how fast it is removed
- How the study agent is acting on your body
- DNA damage response (DDR) mutations documented in the past medical record or confirmed during the screening period. (Ataxia telangiectasia mutated (ATM), FANCC, MRE11A, Breast Cancer Gene 2 (BRCA2), MLH1, poly-ADP ribose polymerase 1 (PARP1), Breast cancer Gene 1 (BRCA1), PMS2, checkpoint kinase1 (CHEK1), checkpoint kinase2 (CHEK2), RAD51C, poly-ADP ribose polymerase 2 (PARP2), methylthioadenosine phosphorylase (MTAP), MUTYH, ERCC4, poly-ADP ribose polymerase 3 (PARP3), ataxia telangiectasia and Rad3-related kinase (ATR), FANCG, RAD51B, FANCA, RAD51, RAD51D, BRCA1 interacting protein 1 (BRIP1), FANCL, RAD52, mutS homolog 6 (MSH6), POLE, RAD54L, partner and localizer of BRCA2 (PALB2), polymerase delta 1 (POLD1), XRCC2, mutS homolog 2 (MSH2), NBN, cyclin dependent kinase 12 (CDK12), AT-rich interactive domain-containing protein 1A (ARID1A), ATRX, CDKN2A, p53, Rb, Myc, CyclinE and PD-L1, or advanced Merkel cell carcinoma (MCC))
- Measurable disease defined by RECIST 1.1.
- Life expectancy ≥ 3 months.
- Subject must be capable of oral administration of study medication.
- Subject has had a cytotoxic chemotherapy, immunotherapy, radiotherapy or other targeted therapies within 4 weeks.
- Surgical procedure performed within 7 days prior to first scheduled dose of ATRN-119.
- Concomitant treatment with strong inhibitors or inducers of CYP3A4 and CYP2D6.
- Known human immunodeficiency virus infection (HIV).
- Subjects with active viral or bacterial infections and/or receiving systemic antibiotics or anti-viral medications.
- Current or past diagnosis of leukemia within the past 5 years.
- Prior radiotherapy at the target lesion unless there is evidence of disease progression.
- Known CNS metastases or clinical evidence of CNS involvement that is not stable for previous 1 month by radiology documentation (magnetic resonance imaging [MRI] brain).
- History of non-malignant gastronintestinal (GI) bleeding, gastric stress ulcerations, or peptic ulcer disease within the past 3-months.
- Patient has uncontrolled hypertension at time of enrollment.
- Complete left bundle branch block (LBBB), bifascicular block (right bundle branch block [RBBB] with either left anterior hemiblock or left posterior hemiblock).
- Any clinically significant ST segment and/or T-wave abnormalities.
- Myocardial infarction or unstable angina pectoris within 6 months prior to starting study medication.
advanced solid tumor that has at least one DNA damage response (DDR) mutations documented in the past medical record or confirmed during the screening period.
Location
Similar Trials
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.